Literature DB >> 1905302

High-performance liquid chromatographic analysis of 2',3'-dideoxyinosine in biological samples.

M G Wientjes1, J L Au.   

Abstract

A high-performance liquid chromatographic analysis for the anti-AIDS drug 2',3'-dideoxyinosine (ddI) in rat plasma and urine, with a limit of detection of 0.2 microgram/ml and requiring a sample size of 100 microliters is described. Diluted plasma or urine samples were extracted using a C18 solid-phase extraction column. Retention of ddI on more polar solid-phase extraction columns was insufficient for sample clean-up. This method is useful for pharmacokinetic studies of ddI in small rodents.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1905302     DOI： 10.1016/0378-4347(91)80048-h

Source DB:  PubMed          Journal:  J Chromatogr


  6 in total

1.  Extensive absorption of 2',3'-dideoxyinosine by intratracheal administration in rats.

Authors:  X Gao; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

2.  Pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and pentamidine in rats.

Authors:  T K Yeh; H J Kang; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

3.  Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats.

Authors:  M G Wientjes; J L Au
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

4.  Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum.

Authors:  S L Bramer; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

5.  Nonlinear disposition of intravenous 2',3'-dideoxyinosine in rats.

Authors:  M G Wientjes; E Mukherji; J L Au
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

6.  Percutaneous absorption of 2',3'-dideoxyinosine in rats.

Authors:  E Mukherji; N J Millenbaugh; J L Au
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.